breast%20cancer
BREAST CANCER
Breast cancer is the presence of malignant breast nodule, mass or abscess.
Most common symptom of breast cancer is a new lump or mass in the breast. The lump or mass is usually painless, hard & irregular but it can also be tender, soft, rounded or painful.
Other signs & symptoms include breast pain or nipple pain, nipple discharge, nipple retraction and presence of breast skin changes (eg peau d' orange, nipple excoriation, scaling, inflammation, skin tethering, ulceration, abscess).

Radiotherapy

  • Treatment with high-energy rays or particles that destroy cancer cells
  • Also used to treat cancer that has metastasized to other organs
  • Breast RT strongly recommended after breast-conserving surgery to decrease the chance of recurrence
  • Can be given as external beam radiation therapy (EBRT) or brachytherapy
Whole Breast Radiation Therapy (WBRT)
  • Targets the entire breast tissue
  • Recommended for patients with DCIS who had breast-conserving surgery and for postlumpectomy patients to decrease the chance of recurrence
  • Recommended dose: 45-50.4 Gy in 25-28 fractions or 40-42.5 Gy in 15-16 fractions with or without boost to tumor bed at 10-16 Gy in 4-8 fractions to be given 5 days per week
  • Boost RT to tumor bed further reduces the risk for disease relapse especially in patients at high-risk for local recurrence (>50 years old, with grade 3 tumors, with vascular invasion or extensive intraductal component and radical tumor excision)
Chest Wall Radiotherapy
  • Targets the ipsilateral chest wall, mastectomy scar, and may also drain indicated sites
  • Recommended dose: 45-50.4 Gy in 25-28 fractions to the chest wall with or without scar boost at 1.8-2 Gy per fraction; total dose of approximately 60 Gy, to be given 5 days per week
Regional Nodal Radiation
  • Recommended for patients with LN involvement
  • CT-based planning is recommended
  • Recommended dose: 45-50.4 Gy in 25-28 fractions to the regional nodal fields, to be given 5 days per week
Accelerated Partial-breast Irradiation (APBI)
  • Treatment option in patients with low-risk for local recurrence, especially if with history of adjuvant endocrine therapy
  • May consider APBI in low-risk patients if any one of the following is present:
    • ≥50 years old with invasive ductal carcinoma ≤2 cm (T1) with negative margin widths of ≥2 mm, no LN involvement, ER-positive and BRCA-negative
    • Low/intermediate nuclear grade DCIS detected during screening measuring ≤2.5 cm with negative margin widths of ≥3 mm
  • May also be considered in patients with DCIS
  • Recommended dose: 34 Gy in 10 fractions given 2x/day with brachytherapy or 38.5 Gy fractions 2x/day via EBRT

Radiotherapy for Invasive Breast Cancer Stage I, IIa, IIb, IIIa (T3N1M0)
Postmastectomy Radiotherapy

  • Radiotherapy to the chest wall, infraclavicular region, supraclavicular area, and internal mammary nodes and to any area of involved axillary nodes is recommended for patients with ≥4 positive axilllary nodes
  • Radiotherapy to the chest wall, infraclavicular region, supraclavicular area, and internal mammary nodes and to any area of involved axillary nodes should be strongly considered in patients with 1-3 positive axilllary nodes
  • Radiotherapy to the chest wall, with or without coverage of the supraclavicular and infraclavicular region, supraclavicular area, and internal mammary nodes and any area of involved axillary nodes, may be considered in patients without any involved axilllary nodes but with tumor >5 cm in size and those with positive margins if re-excision is not feasible
  • Radiotherapy to the chest wall, with or without regional nodal radiation in patients with central or medial tumors, tumor >2 cm in size and with other high-risk features should be considered in patients without axillary node involvement, tumor ≤5 cm, and negative margins but <1 mm
  • Commonly done after chemotherapy except in patients with negative axillary nodes and tumor with ≤5 cm in size and margins ≥1 mm
Post-lumpectomy Radiotherapy
  • Radiotherapy to the whole breast with or without boost to tumor bed, supraclavicular and infraclavicular areas, and internal mammary nodes, and within the area of involved axillary nodes is recommended for patients with ≥4 positive axilllary nodes
  • Radiotherapy to the whole breast with or without boost to tumor bed is recommended for patients with 1-3 positive axillary nodes, with consideration for supraclavicular, infraclavicular, and internal mammary node radiotherapy and to any area of involved axillary nodes
  • Radiotherapy to the whole chest with or without boost to tumor bed is recommended in patients negative for axillary node involvement
    • May consider regional nodal radiation with exclusion of the dissected portion of the axilla in high-risk patients with tumors >2 cm in size or with tumors located near or at the center
  • Commonly done after chemotherapy

Radiotherapy for Invasive Breast Cancer Stage IIIa (except T3N1M0), IIIB, IIIC

  • Adjuvant radiotherapy to the chest wall, infraclavicular region, suprclavicular area, and internal mammary nodes and to any area of involved axillary nodes should be considered in postmastectomy patients at risk of invasive disease and axillary lymph node involvement and indicated if with node involvement
  • Whole breast radiotherapy with or without boost to the tumor bed instead of chest wall radiotherapy is recommended for postlumpectomy patients
    • RT to the infraclavicular region, supraclavicular area, and internal mammary nodes and to any area of involved axillary nodes should be considered in postlumpectomy patients at risk of invasive disease and axillary lymph node involvement and should be done if positive for node involvement
  • For patients with inoperable tumor upon initial diagnosis with positive response to preoperative systemic therapy and subsequently underwent surgery, adjuvant radiotherapy to the whole breast/chest wall, infraclavicular region, supraclavicular area, internal mammary nodes and to any area of involved axillary nodes is recommended
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
Adding the CDK4/6 inhibitor abemaciclib to an endocrine therapy of fulvestrant extends overall survival (OS) compared with fulvestrant alone in East Asian patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who have progressed on prior endocrine therapy, consistent with results from the overall population, updated analysis of the global, phase III MONARCH 2 study has shown.
01 Sep 2020
Acute diarrhoea is the second leading cause of deathin children aged younger than 5 years, accounting forapproximately 1.9 million deaths worldwide each year;however, diarrhoea is a preventable and treatable condition.In Malaysia, acute gastroenteritis accounts for about 1.3%of all deaths in children aged younger than 5 years annually.Diarrhoea is defined as the passage of three or more looseor watery stools within 24 hours, and it may be clinicallycategorised as either acute watery diarrhoea (AWD), acutebloody diarrhoea, persistent diarrhoea or diarrhoea withsevere malnutrition.